Free Trial

Alzamend Neuro Q4 2023 Earnings Report

Alzamend Neuro logo
$1.11 -0.14 (-11.20%)
(As of 12/20/2024 05:51 PM ET)

Alzamend Neuro Earnings Headlines

Crypto’s hidden gem + greatest crypto bull run in history = $$$?
You don’t actually want to buy Bitcoin this time around. That’s because there’s a better way to take advantage of this new bull market… One market expert calls it Crypto’s Hidden Gem And it’s a new way that has given folks like you and me the chance to see bigger and faster moves than the traditional way of buying Bitcoin… That means if you’ve stayed away from Bitcoin and crypto because it's confusing or seems risky… This is a much safer and better approach to ride this years’ crypto bull run. Because believe it or not… The 2024 crypto bull run is one you DON’T want to miss.
Alzamend Neuro says net cash gained by financing activity $8.3M
See More Alzamend Neuro Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Alzamend Neuro? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Alzamend Neuro and other key companies, straight to your email.

About Alzamend Neuro

Alzamend Neuro (NASDAQ:ALZN), an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

View Alzamend Neuro Profile

More Earnings Resources from MarketBeat

Upcoming Earnings